Intracranial progression occurred in 15 out of 40 breast carcinoma patients and the 11 out of 15 S100A4-positive cases showed significantly earlier intracranial progression (median 9.77 months, 95% CI: 8.28–11.25) than the 4 out of 15 negatively stained cases (median 27.03 months, 95% CI: 18.46–35.60, Log rank test, P=0.023; Figure 4B). Here, S100A4 is linked to breast carcinoma.